JP2023540464A5 - - Google Patents
Info
- Publication number
- JP2023540464A5 JP2023540464A5 JP2023512663A JP2023512663A JP2023540464A5 JP 2023540464 A5 JP2023540464 A5 JP 2023540464A5 JP 2023512663 A JP2023512663 A JP 2023512663A JP 2023512663 A JP2023512663 A JP 2023512663A JP 2023540464 A5 JP2023540464 A5 JP 2023540464A5
- Authority
- JP
- Japan
- Prior art keywords
- promoter
- sequence
- acid sequence
- poly
- codon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010706505.5A CN113952473A (zh) | 2020-07-21 | 2020-07-21 | 用于治疗眼部疾病的组合物和方法 |
| CN202010706658.XA CN113952474A (zh) | 2020-07-21 | 2020-07-21 | 用于治疗眼部疾病的组合物和方法 |
| PCT/IB2021/000498 WO2022018516A1 (en) | 2020-07-21 | 2021-07-20 | Composition and method for treating eye diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023540464A JP2023540464A (ja) | 2023-09-25 |
| JP2023540464A5 true JP2023540464A5 (https=) | 2024-07-26 |
| JP7842082B2 JP7842082B2 (ja) | 2026-04-07 |
Family
ID=79728536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023512663A Active JP7842082B2 (ja) | 2020-07-21 | 2021-07-20 | 眼疾患を処置するための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230295243A1 (https=) |
| EP (1) | EP4185333A4 (https=) |
| JP (1) | JP7842082B2 (https=) |
| CN (1) | CN116323949A (https=) |
| AU (1) | AU2021313839A1 (https=) |
| CA (1) | CA3186830A1 (https=) |
| WO (1) | WO2022018516A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3727468A4 (en) | 2017-12-19 | 2021-09-22 | Akouos, Inc. | AAV-MEDIATED THERAPEUTIC ANTIBODIES DELIVERY TO THE INTERNAL EAR |
| IL303317A (en) | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| US20250137011A1 (en) * | 2022-02-02 | 2025-05-01 | Adverum Biotechnologies, Inc. | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept |
| CN120826472A (zh) * | 2023-03-10 | 2025-10-21 | 阿德夫拉姆生物技术股份有限公司 | 昆虫细胞中重组腺相关病毒（rAAV）的生产 |
| WO2025030169A2 (en) * | 2023-08-03 | 2025-02-06 | Arcum Vision Inc. | Enhanced formulation of polymyxin b/ trimethoprim and rifampin and methods for ophthalmic uses |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004037611B4 (de) * | 2004-08-03 | 2013-10-02 | Geneart Ag | Induzierbare Genexpression |
| ATE453716T1 (de) * | 2004-08-03 | 2010-01-15 | Geneart Ag | Verfahren zur modulation der genexpression durch änderung des cpg gehalts |
| WO2015109898A1 (zh) * | 2014-01-24 | 2015-07-30 | 上海恒瑞医药有限公司 | VEGF与PDGFRβ双特异性融合蛋白及其用途 |
| AU2016219789B2 (en) * | 2015-02-20 | 2021-03-25 | Fondazione Telethon | Methods and compositions for treating genetic eye diseases |
| ES2840059T3 (es) * | 2016-06-16 | 2021-07-06 | Adverum Biotechnologies Inc | Tratamiento de la DMRE mediante el uso de la variante AAV2 con aflibercept |
| AU2018350990A1 (en) * | 2017-10-18 | 2020-05-21 | Regenxbio Inc. | Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified VEGF-Trap |
| CN111770999A (zh) | 2017-11-27 | 2020-10-13 | 4D分子治疗有限公司 | 腺相关病毒变体衣壳和用于抑制血管生成的应用 |
| EP3727468A4 (en) * | 2017-12-19 | 2021-09-22 | Akouos, Inc. | AAV-MEDIATED THERAPEUTIC ANTIBODIES DELIVERY TO THE INTERNAL EAR |
| MX2020010465A (es) * | 2018-04-03 | 2021-01-08 | Vectores de virus para direccionamiento a tejidos oftalmicos. | |
| JP2022513067A (ja) | 2018-11-16 | 2022-02-07 | アスクレピオス バイオファーマシューティカル， インコーポレイテッド | ポンペ病を処置するための治療用アデノ随伴ウイルス |
| HRP20260137T1 (hr) | 2019-09-11 | 2026-03-13 | Adverum Biotechnologies, Inc. | Liječenje očnih neovaskularnih bolesti upotrebom aav2 varijanti koje kodiraju aflibercept |
| CR20230202A (es) * | 2020-10-16 | 2023-06-13 | Gyroscope Therapeutics Ltd | Ácido nucleico que codifica una entidad anti-vegf y un regulador del complemento negativo y sus usos para el tratamiento de la degeneración macular relacionada con la edad |
| BR112023020490A2 (pt) * | 2021-04-09 | 2023-11-21 | Avirmax Biopharma Inc | Composições e métodos para expressão de transgenes oculares |
| IL307416A (en) * | 2021-04-27 | 2023-12-01 | 4D Molecular Therapeutics Inc | Preparations and methods for the treatment of eye disease related to the formation of blood vessels |
| US20240252679A1 (en) * | 2021-05-28 | 2024-08-01 | Shanghai Regenelead Therapies Co., Ltd. | Recombinant adeno-associated virus having variant capsid, and application thereof |
-
2021
- 2021-07-20 JP JP2023512663A patent/JP7842082B2/ja active Active
- 2021-07-20 WO PCT/IB2021/000498 patent/WO2022018516A1/en not_active Ceased
- 2021-07-20 CN CN202180064547.6A patent/CN116323949A/zh active Pending
- 2021-07-20 CA CA3186830A patent/CA3186830A1/en active Pending
- 2021-07-20 AU AU2021313839A patent/AU2021313839A1/en active Pending
- 2021-07-20 EP EP21845723.2A patent/EP4185333A4/en active Pending
-
2023
- 2023-01-20 US US18/157,599 patent/US20230295243A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023540464A5 (https=) | ||
| AU2022203494B2 (en) | Adeno-Associated Virus Variant Capsids And Use For Inhibiting Angiogenesis | |
| RU2725286C2 (ru) | Варианты капсидов аденоассоциированного вируса и способы их применения | |
| EP3448437B1 (en) | Evasion of neutralizing antibodies by a recombinant adeno-associated virus | |
| US10494619B2 (en) | High isomerohydrolase activity mutants of human RPE65 | |
| TW202313096A (zh) | 衣殼變異的重組腺相關病毒及其應用 | |
| US20240091383A1 (en) | Synergistic effect of smn1 and mir-23a in treating spinal muscular atrophy | |
| CN110650733A (zh) | 经过修饰的aav衣壳和其用途 | |
| CN110461368A (zh) | 具有变异衣壳的腺相关病毒病毒体及其使用方法 | |
| KR20190032375A (ko) | 신규 아데노-관련 바이러스 캡시드 단백질 | |
| WO2012145601A2 (en) | Adeno-associated virus virions with variant capsid and methods of use thereof | |
| EP3978614A2 (en) | Single-vector gene construct comprising insulin and glucokinase genes | |
| JP2021534814A5 (https=) | ||
| JP2024105661A (ja) | 眼疾患に対するａｄｅｎｏ随伴ウイルス連ウイルスベクター媒介遺伝子治療 | |
| CN118853712A (zh) | 编码抗vegf蛋白的核酸、多核苷酸表达盒及重组腺相关病毒 | |
| JP2023535232A5 (https=) | ||
| WO2016037931A1 (en) | Nucleic acid constructs and expression vectors for gene therapy of acute porphyrias and other diseases | |
| EP4516913A1 (en) | Aav vector optimized for intrathecal administration into which hepatocyte growth factor gene is introduced | |
| WO2025214408A9 (en) | Optogenetic modulation for vision restoration | |
| CN117070541A (zh) | 编码抗vegf蛋白的多核苷酸表达盒、质粒及重组腺相关病毒 | |
| KR20010040309A (ko) | 여러 개의 아데노수반 바이러스 벡터를 사용하여 다수의유전자를 세포 내로 전달하는 방법 | |
| HK40110810A (zh) | 一种基因调节的方法及其应用 | |
| RU2024110159A (ru) | Генная терапия фратаксином | |
| CN117070540A (zh) | 编码抗vegf蛋白的多核苷酸表达盒、质粒及重组腺相关病毒 | |
| CN121406675A (zh) | 一种新型基因治疗药物 |